Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc. (NASDAQ: AURA) will have its CEO participating in upcoming investor conferences to discuss the company's precision immunotherapies for solid tumors.
Rhea-AI Summary
Aura Biosciences, Inc. (NASDAQ: AURA) will have its CEO participating in upcoming investor conferences to discuss the company's precision immunotherapies for solid tumors. The webcasts will be available on the company's website for 90 days after the presentation date.
Details
News Market Reaction – AURA
The recorded move for AURA in the trading session of this news was -1.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
- The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.
Fireside Chat at 9:00 a.m. ET.
- TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024.
Fireside Chat at 10:00 a.m. ET.
The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA. For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.
Investors and Media:
Alex Dasalla
Head of Investor Relations and Corporate Communications
adasalla@aurabiosciences.com
Source: Aura Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.